Olpasiran (AMG890) is an experimental antisense therapy designed to lower the level of lipoprotein(a), which is believed to be a causal factor in the development of cardiovascular disease.
The drug is developed by Amgen.
[1][2]
This pharmacology-related article is a stub.
You can help Wikipedia by expanding it.